Cancer-Focused Coeptis Therapeutics Turns To SPAC Deal To Uplist To NASDAQ

Coeptis Therapeutics Inc COEP has agreed to a $175 million merger deal with Bull Horn Holdings Corporation BHSE, a special purpose acquisition company.
Upon completing the deal, Bull Horn will be rebranded and operate as Coeptis Therapeutics Holdings Inc. and is expected to be listed on Nasdaq under the ticker symbol COEP.
With this transaction, expected to be completed in the third quarter, the shareholders of Coeptis will receive equity in Bull Horn valued at $175 million.
Related: Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform.
The merger is anticipated to push Coeptis' efforts to boost its cell therapy platforms to treat cancer.
Coeptis is a developer of cell therapy platforms for cancer. Its product portfolio is highlighted by a cell therapy technology (CD38-GEAR-NK) and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which Coeptis is co-developing with VyGen-Bio Inc.
CD38-GEAR-NK is a natural killer (NK) cell-based investigational therapeutic that enables combination therapy with anti-CD38 monoclonal antibodies (mAbs).
Coeptis' current President and CEO, David Mehalick, will lead the combined company as President & CEO. The current Chief Financial Officer of Bull Horn, Chris Calise, will join the post-closing Board of Directors.
Price Action: COEP shares are down 26.6% at $4.11 during the market session on the last check Wednesday.